Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFB): a clinical study protocol

Colin E Swenson,William R Hunt,Candela Manfredi,Diana J Beltran,Jeong S Hong,Brian R Davis,Shingo Suzuki,Cristina Barillá,Andras Rab,Cynthia Chico,Joy Dangerfield,Ashleigh Streby,Elizabeth M Cox,Arlene Stecenko,Adrianna Westbrook,Rebecca Kapolka,Eric J Sorscher

DOI: https://doi.org/10.1101/2024.07.19.24310604

2024-07-21

Abstract:Non-cystic fibrosis bronchiectasis (NCFB) is a disease characterized by abnormal dilatation of the airways, airflow obstruction, persistent cough, excessive sputum production and recurrent lung infections. NCFB exhibits clinical and pathological manifestations similar to key features of cystic fibrosis (CF) lung disease. In CF, pathogenesis results from dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR), and diagnosis is made by demonstrating elevated sweat chloride concentrations (typically ≥60 mEq/L), two CFTR mutations known to be causal, multi-organ tissue injury, or combination(s) of these findings. Based on a considerable body of evidence, we believe many patients with NCFB have disease likely to benefit from drugs such as elexacaftor/tezacaftor/ivacaftor (ETI) that activate CFTR-dependent ion transport. ETI is currently prescribed solely for treatment of CF, and has not been adequately tested or proposed for patients with NCFB, many of whom exhibit decreased CFTR function. Accordingly, we are conducting a clinical trial of ETI in subjects carrying a diagnosis of NCFB. Participants will exhibit one disease-causing CFTR mutation and/or sweat chloride measurements of 30-59 mEq/L. Cutaneous punch biopsy or blood samples will be obtained for iPS cell differentiation into airway epithelial monolayers – which will then be tested for response to ETI. Each patient will be given CFTR modulator treatment for approximately four weeks, with monitoring of clinical endpoints that include FEV1, sweat chloride, quality of life questionnaire, and weight. The study will evaluate response of patients with NCFB to ETI, and test usefulness of iPSC-derived airway epithelial monolayers as a novel in vitro technology for predicting clinical benefit.

Respiratory Medicine

What problem does this paper attempt to address?

The main objective of this paper is to evaluate the therapeutic effects of the drug combination elexacaftor/tezacaftor/ivacaftor (ETI, marketed as Trikafta™) in patients with non-cystic fibrosis bronchiectasis (NCFB). Specifically, the study aims to address the following key questions:

1. **Explore the efficacy of ETI in NCFB patients**: Since ETI is currently approved only for the treatment of cystic fibrosis (CF), researchers hope to assess through this clinical trial whether this drug combination can also improve respiratory function and other related indicators in NCFB patients.

2. **Validate the effectiveness of induced pluripotent stem cell (iPSC)-derived airway epithelial monolayers as a tool to predict the clinical benefits of ETI**: By obtaining skin biopsy samples or blood samples from NCFB patients and reprogramming these cells into iPSCs, which are then further differentiated into airway epithelial cells, researchers aim to determine whether the response of these cells to ETI can predict the actual clinical outcomes when patients receive the treatment.

3. **Evaluate the safety and tolerability of ETI**: The study will also monitor the safety of the drug, including the incidence of adverse events and changes in laboratory test results.

The primary study subjects are NCFB patients with a CFTR pathogenic mutation and/or sweat chloride measurements between 30-59 mEq/L. The study plans to recruit approximately 30 participants and administer ETI treatment for about 4 weeks. Primary endpoints include the response of iPSC-derived cells to ETI and lung function tests (FEV1) at week 4 of treatment. Secondary endpoints include sweat chloride levels, quality of life questionnaires, weight changes, and safety evaluations.

In summary, this study aims to fill the gap in treatment options for NCFB patients by exploring the potential benefits of ETI in this disease context, while also validating a new in vitro model (iPSC-derived airway epithelial monolayers) for predicting clinical drug efficacy.